Journal of Clinical and Experimental Ophthalmology
Open Access

Comparison of the one-year outcomes of conbercept therapy between two different angiographic subtypes of polypoidal choroidal vasculopathy

6^th Global Ophthalmologists Annual Meeting

May 16-18, 2016 Osaka, Japan

Yong Cheng

Peking University, China

Scientific Tracks Abstracts: J Clin Exp Ophthalmol

Abstract :

Objectives: To compare the outcomes of conbercept therapy between two different angiographic subtypes of polypoidal choroidal vasculopathy (PCV) Methods: Fifty-eight patients of PCV were classified into two phenotypes according to indocyanine green angiography (ICGA). In type-1, both feeder and draining vessels are visible on ICGA and network vessels are numerous. In type-2, neither feeder nor draining vessels are detectable and the number of network vessels is small. The patients were treated with intravitreal conbercept (IVC) for 3 months. Additional IVC was given at subsequent monthly visits, if needed. The patients were followed-up for 12 months and changes in mean BCVA, central retinal thickness (CRT), serous retinal detachment (SRD), hemorrhage and number of polypoidal lesions were evaluated. Results: The mean BCVA in type-2 PCV (15.92�?�?�?�??�?�??�?±9.7614.10�?�?�?�??�?�??�?±9.07) achieved a significantly greater improvement in than the type-1 (14.10�?�?�?�??�?�??�?±9.07) at month 12 (p<0.01). And the mean CRT decrease was numerically greater in type-2 (120.44�?�?�?�??�?�??�?±73.81) compared with type-1 (106.48�?�?�?�??�?�??�?±72.33) at month 6 (p<0.01) and greater in type-2 (130.21�?�?�?�??�?�??�?±76.28) compared with type-1 (111.67�?�?�?�??�?�??�?±79.57) at month 9 (p<0.01). There was no significant difference between the two groups for the decrease in SRF thickness, PED height and regression of polyps from month 3 to 12 (p>0.05). Conclusions: Classification systems for PCV will show differences in presentation, natural history or response to anti-VEGF treatment and might therefore provide a new key to the choice of treatment of the disease.

Biography :

Yong Cheng has completed his MD from Peking University. He specializes in vitreo-retinal disorders that require either medical or surgical treatment. He has taken part in lots of multicenter research and published more than 10 papers in reputed journals.

Email: raccocheng@126.com